Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: SIX Swiss Ex
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

ATLN:VX

133.300 CHF 0.100 0.08%

As of 03:01:35 ET on 05/29/2015.

Snapshot for Actelion Ltd (ATLN)

Open: 133.100 Day's Range: 133.100 - 133.400 Volume: 4,475
Previous Close: 133.200 52wk Range: 86.708 - 134.900 1-Yr Rtn: +51.19%

Stock Chart for ATLN

No chart data available.
  • ATLN:VX 133.300
  • 1D
  • 1M
  • 1Y
133.200
Interactive ATLN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ATLN

Current P/E Ratio (ttm) 23.6590
Estimated P/E(12/2015) 24.3332
Relative P/E vs. SMI 1.1884
Earnings Per Share (CHF) (ttm) 5.6300
Est. EPS (CHF) (12/2015) 5.4740
Est. PEG Ratio 2.1189
Market Cap (M CHF) 15,201.91
Shares Outstanding (M) 114.13
30 Day Average Volume 618,017
Price/Book (mrq) 7.6719
Price/Sale (ttm) 7.3916
Dividend Indicated Gross Yield 0.98%
Cash Dividend (CHF) 1.3000
Dividend Ex-Date 05/12/2015
5 Year Dividend Growth -
Next Earnings Announcement 07/21/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ATLN

  • Revenue
  • Net Income (M/CHF)
  • Profit Margin (%)

Company Profile & Key Executives for ATLN

Actelion Ltd is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for diseases with significant unmet medical needs. The Company focuses in the field of pulmonary arterial hypertension (PAH) with treatments for diseases from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

Jean-Paul ClozelCEO/Co-FounderAndre C MullerExec VP/CFO
Otto SchwarzExec VP/COONicholas FrancoExec VP/Chief Bus Dev Officer
More Company Profile & Key Executives for ATLN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil